Salicylate-induced kidney mitochondrial permeability transition is prevented by cyclosporin A

Toxicology Letters

Volumn 105, Issue 1, 1999, Pages 1-8

  Al Nasser, Ibrahim A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Aspirin; Calcium; Cyclosporin A; Kidney mitochondria; Salicylate

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM ION; CYCLOSPORIN A; PHOSPHATE; SALICYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TOXICITY; KIDNEY; MALE; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MITOCHONDRION SWELLING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CALCIUM; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MITOCHONDRIA; MITOCHONDRIAL SWELLING; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SALICYLIC ACID;

EID: 0033039979     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00373-7     Document Type: Article

References (34)

1. 2+-induced permeabilisation of rat liver mitochondria. Biochem. J. 239:1986;19-24.
2. 2+-induced depolarisation of renal cortex mitochondria. Med. Sci. Res. 21:1993;647-649.
3. Al-Nasser I., Campbell P. Cyclosporin A inhibition of phosphate-induced calcium release from rat kidney cortex mitochondria. Med. Sci. Res. 21:1993;777-779.
4. 2+-induced permeabilisation of pancrease mitochondria by cyclosporin. A. Med. Sci. Res. 25:1997;783-786.
5. 2+-activated inner membrane pore of heart mitochondria. Eur. J. Biochem. 230:1995;1125-1131.
6. Baggot J., Morgan S., Ha T., Vaughn W., Hine R. Inhibition of folate-dependent enzymes by non-steroidal anti-inflamatory drugs. Biochem. J. 282:1992;197-202.
7. 125-diatrizoate. Br. Med. J. 1:1971;707-708.
8. Berg K.J. Acute effects of acetylsalicylic acid on renal function in normal man. Eur. J. Clin. Pharmacol. 11:1977;117-123.
9. Berg K. Acute flank pain and reversible renal dysfunction with nonsteroidal anti-inflammatory. Peadiatrics. 92:1993;459-460.
10. Bernardi P., Petronili V. The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. J. Bioenerg. Biomembr. 24:1996;77-90.
11. 2+. Biochem. Pharmacol. 50:1995;497-500.
12. . Brown R., Forman T. The biochemistry of Reye's syndrome. CRC Crit. Rev. Clin. Lab. Sci. 17:1982;247-297.
13. 2+ overload. Eur. J. Biochem. 178:1988;489-501.
14. Griffith E., Halestrap A. Further evidence that cyclosporin A protect mitochondria from calcium overload by inhibiting matrix peptidyl-prolyl cis-trans isomerase. Biochem. J. 274:1991;611-614.
15. Gutknecht J. Salicylates and proton transport through lipid bilayer membranes. A model for salicylate-induced uncoupling and swelling in mitochondria. J. Membr. Biol. 115:1990;253-260.
16. Heubi J., Parline J., Schubery W. Reye's syndrome: current concepts. Hepatology. 7:1987;155-164.
17. Kamo N., Muratsugo M., Ruyi H., Kobatake J. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relation between proton electrochemical potential and phosphorylation potential in steady state. J. Membr. Biol. 48:1979;105-121.
18. Kauffman G. Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology. 96:1989;606-614.
19. Korger A., Klingenberg M. A modified biuret method for the determination of protein. Biochem. Z. 344:1966;317-338.
20. Martiens E., Lee C. Reye's syndrome: salicylate and mitochondrial functions. Biochem. Pharmacol. 33:1984;2869-2876.
21. m overload in rat heart. Am. J. Physiol. 271:1996;H2145-H2153.
22. Nazareth W., Yafei M., Crompton M. Inhibition of anoxia-induced injury in heart myocytes by cylosporin A. J. Mol. Cell. Cardiol. 23:1991;1351-1354.
23. Nicolli A., Basso E., Petronilli V., Wenger P., Bernardi P. Interaction of cyclophilin with mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. J. Biol. Chem. 271:1996;2185-2191.
24. Peng C., Kane J., Slaub K., Murphy M. Improvement of mitochondrial energy production in ischaemic myocardium by in vivo infusion of ruthenium red. Cardiovasc. Pharmacol. 2:1980;45-54.
25. Petit P., Susin S., Zamzami N., Mignotte B., Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett. 396(3):1996;7-13.
26. Pinsky P., Hurwitz E., Schonberger L., Gunny W. Reye's syndrome and aspirin. Evidence for a dose-response effect. J. Am. Med. Assoc. 260:1988;657-661.
27. Rainsford K. Aspirin and the Salicylates. 1984;Butterworths, New York.
28. Robert M., Fillastre J., Berger H., Malanidian H. Effect of intravenous infusion of acetyl salicylate acid on renal function. Br. Med. J. 2:1972;466-467.
29. Trost L., Lemasters J. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J. Pharmacol. Exp. Ther. 278:1996;1000-1005.
30. Trost L., Lemasters J. Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: implications for Reye's syndrome. Toxol. Appl. Pharmacol. 147:1997;431-441.
31. Waldman R., Hall W., McGee H., Vanamburg G. Aspirin as a risk factor in Reye's syndrome. J. Am. Med. Assoc. 247:1982;3089-3094.
32. Wu K. Biochemical pharmacology of nonsteroidal anti-inflammatory drugs. Biochem. Pharmacol. 55:1998;543-547.
33. Yu K. Salicylate and mitochondrial injury in Reye's syndrome. Science. 221:1983;163-165.
34. Zoraiti M., Szabo I. The mitochondrial permeability transition. Biochem. Biophys. Acta. 1241:1995;139-176.